The patent describes technical improvements to the Aethlon Hemopurifier that increase the rate of capture of undesirable blood contaminants including viruses, toxins, and immunosuppressive particles associated with cancer.
James Joyce, chairman and CEO of Aethlon Medical, said: “Our research team has improved the capability of our Hemopurifier to remove contaminants from the blood. The related patent submission reflects an ongoing strategy to protect our developments and further increase the breadth of our intellectual property estate.”